TABLE 1.

TKI treatment concentration and the solvent information. The stock solution of each TKI was diluted to the working concentration using the corresponding solvent. The appropriate amount of working concentration was then added to the media in the Petri dish containing iPSC-CMs to arrive to the final concentration.

Drug_ID	DrugName	Stock concentration (mM)	Working concentration	Final concentration	Solvent
AFA	Afatinib	10	50 uM	50 nM	DMSO
AXI	Axitinib	10	250 uM	200 nM	DMSO
BEV	Bevacizumab	0.168	0.5 mM	3uM	Water
BOS	Bosutinib	10	3 mM	100 nM	DMSO
CAB	Cabozantinib	10	1 mM	2 uM	DMSO
CER	Ceritinib	10	200 uM	1 uM	DMSO
CRI	Crizotinib	10	0.168 mM	0.25 uM	DMSO
CTX	Cetuximab	0.014	0.3 mM	1 uM	Water
DAB	Dabrafenib	10	100 uM	2.5 uM	DMSO
DAS	Dasatinib	10	2 mM	0.1 uM	DMSO
ERL	Erlotinib	12	3 mM	3 uM	DMSO
GEF	Gefitinib	10	30 mM	1 uM	DMSO
IMA	Imatinib	10	1 mM	5 uM	Water
LAP	Lapatinib	10	0.25 mM	2 uM	DMSO
NIL	Nilotinib	12	0.014 mM	3 uM	DMSO
PAZ	Pazopanib	10	125 uM	10 uM	DMSO
PON	Ponatinib	10	0.333 mM	100 nM	DMSO
REG	Regorafenib	10	2.5 mM	1 uM	DMSO
RTX	Rituximab	0.07	0.1 mM	3 uM	Water
SOR	Sorafenib	10	1 mM	1 uM	DMSO
SUN	Sunitinib	10	1 mM	1 uM	DMSO
TOF	Tofacitinib	10	10 mM	1 uM	DMSO
TRA	Trametinib	10	5 mM	100 nM	DMSO
TRS	Trastuzumab	3	1 mM	3 uM/10uM	Water
VAN	Vandetanib	10	10uM	333 nM	DMSO
VEM	Vemurafenib	10	1 mM	2uM	DMSO